Venoruton Oxerutins 1g

Venoruton is a well-known pharmaceutical brand specializing in the treatment of chronic venous insufficiency and related symptoms like leg swelling and heaviness. The brand was historically developed by the Swiss pharmaceutical giant Novartis (formerly Zyma SA).

In recent years, the brand underwent a series of ownership changes through joint ventures and divestments. It was part of the GSK Consumer Healthcare portfolio (via the GSK-Novartis joint venture) before being acquired by the STADA Group in 2020 as part of a significant expansion of STADA's consumer health portfolio in Europe.

Manufacturing typically occurs in specialized pharmaceutical facilities across Europe, primarily at the original Swiss production sites or through STADA’s global supply chain network. Today, while Swiss-engineered, it is strictly managed under the STADA umbrella, headquartered in Germany.